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Abstract: BACKGROUND AND PURPOSE We systematically reviewed available evidence for reports
of neurological signs and symptoms in patients with COVID-19 to identify cases with severe acute respi-
ratory syndrome coronavirus (SARS-CoV)-2 infection or immune-mediated reaction in the nervous sys-
tem. METHODS We followed PRISMA guidelines and used the MEDLINE, EMBASE, Google Scholar,
MedRxiv and ChinaXiv databases to search for articles on COVID-19 and nervous system involvement
that were published from 1 January to 24 April 2020. Data on design, sample size, neurological as-
sessment and related work-up were extracted. Biases were assessed with the Newcastle-Ottawa scale.
RESULTS We analysed 27 publications on potential neuroinvasive or parainfectious neurological com-
plications of COVID-19. The reports focused on smell and taste (n = 5) and evaluation of neurological
symptoms and signs in cohorts (n = 5). There were cases of Guillain-Barré syndrome/Miller-Fisher
syndrome/cranial neuropathy (seven cases), meningitis/encephalitis (nine cases) and various other con-
ditions (five cases). The number of patients with examination of cerebrospinal fluid and, in particular,
SARS-CoV-2 polymerase chain reaction was negligible. Two had a positive SARS-CoV-2 polymerase
chain reaction examination of cerebrospinal fluid specimen. Study of potential parenchymal involvement
with magnetic resonance imaging was rare. Only four reports received a rating of the highest quality
standards. CONCLUSIONS This systematic review failed to establish comprehensive insights into ner-
vous system manifestations of COVID-19 beyond immune-mediated complications in the aftermath of
respiratory symptoms. The authors therefore provide guidance for more careful clinical, diagnostic and
epidemiological studies to characterize the manifestations and burden of neurological disease caused by
SARS-CoV-2 on behalf of the Infectious Disease Panel of the European Academy of Neurology.
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Background and purpose: We systematically reviewed available evidence for
reports of neurological signs and symptoms in patients with COVID-19 to
identify cases with severe acute respiratory syndrome coronavirus (SARS-
CoV)-2 infection or immune-mediated reaction in the nervous system.
Methods: We followed PRISMA guidelines and used the MEDLINE,
EMBASE, Google Scholar, MedRxiv and ChinaXiv databases to search for
articles on COVID-19 and nervous system involvement that were published
from 1 January to 24 April 2020. Data on design, sample size, neurological
assessment and related work-up were extracted. Biases were assessed with the
Newcastle–Ottawa scale.
Results: We analysed 27 publications on potential neuroinvasive or parainfec-
tious neurological complications of COVID-19. The reports focused on smell
and taste (n = 5) and evaluation of neurological symptoms and signs in
cohorts (n = 5). There were cases of Guillain-Barre syndrome/Miller-Fisher
syndrome/cranial neuropathy (seven cases), meningitis/encephalitis (nine cases)
and various other conditions (five cases). The number of patients with exami-
nation of cerebrospinal fluid and, in particular, SARS-CoV-2 polymerase
chain reaction was negligible. Two had a positive SARS-CoV-2 polymerase
chain reaction examination of cerebrospinal fluid specimen. Study of potential
parenchymal involvement with magnetic resonance imaging was rare. Only
four reports received a rating of the highest quality standards.
Conclusions: This systematic review failed to establish comprehensive insights
into nervous system manifestations of COVID-19 beyond immune-mediated
complications in the aftermath of respiratory symptoms. The authors therefore
provide guidance for more careful clinical, diagnostic and epidemiological
studies to characterize the manifestations and burden of neurological disease
caused by SARS-CoV-2 on behalf of the Infectious Disease Panel of the
European Academy of Neurology.
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fax: +43 2572 9004 49332; e-mail: j.sellner@salk.at).
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The clinical spectrum of severe acute respiratory syn-
drome coronavirus (SARS-CoV)-2 infection is wide
and encompasses asymptomatic infection, mild upper
respiratory tract illness and severe viral pneumonia
with respiratory failure and sometimes death. From a
neurobiological and translational viewpoint, neurolog-
ical manifestations can be expected in COVID-19.
This is substantiated, on the one hand, by a few cases
with neurological signs and symptoms and detectable
virus load in cerebrospinal fluid (CSF) during the
SARS-CoV-1 epidemic in 2003 [1]. SARS-CoV-1 and
SARS-CoV-2 share genetic sequences but SARS-CoV-
2 has a 10–20 times higher binding affinity to angio-
tensin-converting enzyme-2 [2]. On the other hand,
angiotensin-converting enzyme-2, the functional recep-
tor utilized by SARS-CoV-1 and SARS-CoV-2 for cell
entry, is not only expressed in the lungs but also in
the central nervous system (CNS) [3,4]. Expression of
angiotensin-converting enzyme-2 is found in neurons
and non-neuronal cells, the latter including astrocytes,
oligodendrocytes and olfactory support cells [5,6].
Moreover, infection of neurons with SARS-CoV-1 has
been proven in transgenic mice and several presumed
routes of CNS entry were described in pre-clinical
models [7]. In a report from Wuhan, China, more
than one-third of the hospitalized patients with
COVID-19 had some sort of nervous system-related
clinical signs or symptoms [8]. These included more
specific conditions such as loss of sense of smell or
taste, myopathy and stroke. There were also non-
specific symptoms such as headache, impaired level of
consciousness, dizziness or seizure. From a neuroin-
fectious viewpoint, the relevance of these findings
is limited as these conditions can be coincidental, sec-
ondary to systemic complications or a side-effect of
therapy. Only further diagnostic details such as
focused neuroimaging, evaluation of cardiovascular
risk factors and comorbidities, assessment of pro-
thrombotic or systemic hyperinflammatory states,
presence of intrathecal inflammation and systematic
exclusion of differentials would enable a placement
within the spectrum of COVID-19 complications.
This study therefore aimed to identify clinical cases
of confirmed nervous system invasion or post-infec-
tious neurological disease in the available COVID-19
literature on the basis of a systematic review. Mem-
bers of the Infectious Disease Panel of the European
Academy of Neurology (EAN) compiled guidance for
the diagnostic approach, which emphasizes the
need for precise case definitions and standards for
reporting.
Methods
A systematic review was carried out to study all cases
reporting nervous system involvement in patients with
proven SARS-CoV-2 infection. The protocol followed
the PRISMA guidance for reporting of systematic
reviews. MEDLINE, EMBASE, Google Scholar,
MedRxiv and ChinaXiv databases were searched for
articles published from 1 January 2020 to 24 April
2020 regarding the nervous system and COVID-19.
The search strings for PubMed were as follows:
(("COVID"[All Fields] OR “coronavirus”[All Fields]
OR “SARS-CoV-2”[All Fields]) AND (("neurol-
ogy"[MeSH Terms] OR "neurolog*"[All Fields]) OR
("brain"[MeSH Terms] OR "brain"[All Fields]) OR
("neuro"[All Fields]) OR ("nervous system"[MeSH
Terms] OR "nervous system"[All Fields])) AND
("2020/01/01"[PDAT]: "2020/04/24"[PDAT])). We also
hand-searched reference lists of all articles identified
in the electronic search using common search engines
(e.g. Google, Bing). Ethical approval was not
required.
The search selected studies reporting neurological
features of patients with SARS-CoV-2 infection. Stud-
ies were identified after search and data were extracted
regarding: study design, sample size, neurological
assessment and diagnostic work-up including brain
imaging and CSF analysis. Biases were assessed with
the Newcastle–Ottawa scale [9].
Results
The systematic search yielded 102 papers, of which 30
were eligible for full-text assessment (see Fig. 1 for
PRISMA flow-chart). Four were excluded; these were
commentaries, response letters and review articles
proposing SARS-CoV-2 nervous system invasion but
not comprising clinical findings.
A total of 26 publications reporting neurological
disturbances in patients with SARS-CoV-2 infection
were evaluated; the major readouts are shown in
Table 1. Bias assessment revealed low to fair quality
in more than half of the studies (14/27, 52%), as
shown in Fig. 2. This was mainly due to selection and
reporting bias, as well as on the basis of uncertain
exposure and lack of testing for SARS-CoV-2 with
polymerase chain reaction (PCR) in CSF. Only four
reports reached a rating for high quality; one study
evaluated neurological diagnoses of deceased patients
with COVID-19 [10], another studied neurological
signs and symptoms in a cohort of hospitalized
patients with COVID-19 [8] and the third was a case
series of peripheral nervous system dysfunction with
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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in-depth phenotyping and diagnostic work-up [11].
The fourth study described the clinical characteristics,
laboratory features, treatment and outcomes of cere-
brovascular disease complicating SARS-CoV-2 infec-
tion [12]. Among the 221 consecutively admitted
patients with COVID-19, 11 (5%) had acute ischaemic
stroke, 1 (0.5%) had cerebral venous sinus thrombosis
and 1 (0.5%) had cerebral hemorrhage.
Five observational studies evaluated smell and taste
dysfunction. The first study used an internet-based
platform in adults who underwent testing for COVID-
19 and found a higher rate of smell and taste impair-
ment in SARS-CoV-2-positive patients [13]. The
second report was a European multicenter study of
patients with mild-to-moderate COVID-19, which
used standardized questionnaires [14]. The authors
found olfactory and gustatory dysfunction in 85.6%
and 88.0% of patients, respectively. The third study
used an online checklist for self-reported anosmia/hy-
posmia [15]. In that cohort, 48% had hyposmia or
anosmia and the onset was reported as sudden in
76%. The fourth report was a case-control study of
smell and taste disorders among patients positive for
SARS-CoV-2 on nasopharyngeal swab examination
and also included SARS-CoV-2-negative patients as
controls [16]. The authors found that patients with
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Figure 1 PRISMA flow-chart.
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Table 1 Reports on neurological disorders in association with respiratory severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection




assessment CSF Brain imaging
Other
neurological
work-up Main findings Potential limitations
Bagheri
[15]
Smell Cross-sectional 10 069 No neurological
assessment; smell
loss evaluated with a
self-reported online
questionnaire






























Encephalitis Case series 2 Nasopharyngeal
swab (positive)
CSF (negative)
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No brain MRI, no
CSF viral testing
Filatov [34] Encephalopathy Case report 1 Unspecified Encephalopathy
(patient non-verbal,







































Case 1 had positive
GD1b-IgG, case 2
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NA No Miller-Fisher syndrome
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Not performed NA NA 85.0% of patients had
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GBS developed 22 days
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assessment CSF Brain imaging
Other
neurological
work-up Main findings Potential limitations
Sedaghat
[48]














GBS (AMSAN) 2 weeks
after COVID-19
infection





























tetraparesis (n = 3),







(n = 3), normal
proteins (n = 2);
negative anti-
ganglioside















(n = 3) and
demyelinating
variant (n = 2)
of GBS
GBS developed 5–
10 days after first
symptoms of COVID-
19; response to IVIG
was poor in 2 cases.
SARS-CoV-2 IgG
positive in 3/5 patients.








Seizure Case report 1 Nasoharyngeal
swab











































No brain MRI data,
methods for PCR in
CSF not available








Not performed No No Smell and taste loss in
68% and 71% of
SARS-CoV-2 positive
vs. 16% and 17% in
negative subjects

























































































































assessment CSF Brain imaging
Other
neurological
work-up Main findings Potential limitations













CT: normal No Presumed encephalitis
associated with SARS-
CoV-2 infection
































No Atypical ADEM in a
patient with SARS-
CoV-2
No CSF viral testing,
no spinal cord MRI,
brain MRI atypical
for ADEM















GBS 8 days before
COVID-19 onset
Swab test positive



















7 days after fever onset
No data on spinal
cord MRI, no CSF
analysis, 4/6 swabs
negative
ADEM, acute disseminated encephalomyelitis; AMSAN, acute motor-sensory axonal neuropathy; ARDS, acute respiratory distress syndrome; CNS, central nervous system; CSF, cerebrospinal
fluid; CT, computerized tomography; DWI, diffusion-weighted imaging; EEG, electroencephalography; FLAIR, fluid-attenuated inversion recovery; GBS, Guillain-Barre syndrome; HSV, Herpes
simplex virus; ICU, intensive care unit; Ig, immunoglobulin; IVIG, intravenous immunoglobulin; MRI, magnetic resonance imaging; NA, not available; NCSE, non-convulsive status epilepticus;
PCR, polymerase chain reaction; PNS, peripheral nervous system; RNA, ribonucleic acid; RT-PCR, real-time polymerase chain reaction; aPublication is untraceable in ChinaXiv; data extracted


























































































































































































































































































































Bagheri (2020) [1] 1 1 1 0 1 0 1 1 6 moderate
Beltran-Corbellini (2020) [2] 1 1 1 0 1 0 1 1 6 moderate
Bernard-Valnet (2020) [3] 0 1 1 1 0 1 1 1 6a moderate
Chen (2020)[4] 1 1 1 1 2 1 1 1 9 high
Duong (2020)[5] 0 0 0 1 0 1 1 1 4 low
Filatov (2020)[6] 0 0 0 0 0 1 1 1 3 low
Gutierrez-Ortiz (2020) [7] 0 0 1 1 0 1 1 1 5 moderate
Helms (2020)[8] 1 1 1 1 1 1 1 0 7 fair
Lechien (2020)[9] 1 1 1 1 1 0 1 1 7 fair
Li (2020)[10] 1 1 1 1 1 1 1 1 8 high
Lu (2020) [11] 1 1 1 1 1 0 0 1 6 moderate
Mao (2020)[12] 1 1 1 1 1 1 1 1 8 high
Moein (2020)[13] 1 1 1 0 0 1 1 1 6 moderate
Moriguchi (2020)[14] 1 1
1
a 1 0 1 1 1 7a fair
Padroni (2020) [47] 0 0 1 1 0 1 1 1 5 moderate
Poyiadji (2020)[15] 0 0 1 1 0 1 1 1 5 moderate
Sedaghat (2020)[16] 0 1 0 0 0 1 1 1 4 low
Sharifi-Razavi (2020) [17] 0 0 0 1 0 0 1 1 3 low
Toscano (2020)[18] 1 1
1
a 1 1 1 1 1 8a high




a 1 0 1 0 0 3a
low
Yan (2020)[21] 1 0 1 0 1 0 1 1 5 moderate
Ye (2020)[22] 0 0 0 0 0 1 1 1 3 low
Yin (2020) [23] 0 0 0 1 0 1 1 0 3 low
Zhang (2020) [31] 0 0 0 1 0 1 1 1 4 low
Zhao (2020)[24] 0 1 0 0 0 1 1 1 4 low
Zhao (2020)[25] 0 0 0 1 0 0 1 1 3 low






















Figure 2 Assessment of study bias using the Ottawa–Newcastle scale. CSF, cerebrospinal fluid. [Colour figure can be viewed at
wileyonlinelibrary.com]
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COVID-19 were significantly younger (81%) and had
a high rate of smell (45%) and taste (90%) disorders.
The fifth study found smell dysfunction in 98% of the
SARS-CoV-2 nasopharyngeal swab PCR-positive
patients and reported that this was evident for all 40
odorants studied [17]. The study also had an age- and
sex-matched control group. None of these five studies
provided data on CSF analysis or brain imaging.
Five studies examined neurological disorders in
cohorts. In the first study, hypoxic encephalopathy was
the cause of death in 20% of patients who died from
COVID-19 [10]. The second report assessed neurologi-
cal manifestations in a cohort hospitalized at three ded-
icated COVID-19 inpatient centers [8]. They found that
36.4% of patients had various neurological manifesta-
tions that involved the CNS, peripheral nervous system
and skeletal muscles. Brain imaging, CSF analysis and
further work-up were reported in neither study. The
third study reported neurological features in 90.6% of
consecutive patients admitted because of acute respira-
tory distress syndrome due to COVID-19 and treated
in the intensive care unit [18]. Confusion, agitation,
pyramidal signs and dysexecutive syndrome were the
most common clinical manifestations. Cerebral mag-
netic resonance imaging (MRI) was performed in 13/58
(22%) patients and there was evidence of lep-
tomeningeal enhancement in 62% and ischaemic stroke
in 23% of patients, respectively. Electroencephalogra-
phy (8/58, 14%) and CSF (7/58, 12%) examinations
were performed in some patients. None of the patients
had a pleocytosis in CSF. A multicenter retrospective
study evaluated the occurrence of seizures in patients
with COVID-19 [19]. There was not a single case of
symptomatic seizures or status epilepticus among this
cohort in which patients with epilepsy were excluded
a priori. The fifth study has already been covered above
and concerned the rate of acute cerebrovascular events
(6%) in a cohort of patients with COVID-19 [12]. The
average time from symptoms of SARS-CoV-2 infection
to clinical manifestation of cerebrovascular disease was
10 (interquartile range 1–29) days. The patients with
cerebrovascular disease were significantly older, more
likely to suffer from severe respiratory disease and
more likely to have cardiovascular risk factors and
medical history of cerebrovascular disease. They were
also more likely to have an increased inflammatory
response and hypercoagulable state.
Four publications reported eight cases of Guillain-
Barre syndrome (GBS) in patients with confirmed
SARS-CoV-2 infection. Nerve conduction studies dis-
closed both demyelinating and axonal neuropathies
(n = 4 and n = 4, respectively). All but one case
occurred with a time lag from the respiratory symp-
toms (range 5–22 days). In the remaining case, the
clinical manifestation of GBS preceded COVID-19
symptoms by 8 days [20]. In the case series of five
patients with GBS, three patients had high protein
levels and all tested negative for SARS-CoV-2 in
CSF, as well as for anti-ganglioside antibodies [11].
The other reports did not perform PCR for SARS-
CoV-2 or testing for immunoglobulin (Ig) levels and
did not investigate anti-ganglioside antibodies in CSF
or serum. In addition to the GBS cases, a case of
Miller-Fisher syndrome with positive GD1b-IgG and
a case of multiple cranial neuropathies, both with neg-
ative SARS-CoV-2 PCR in CSF, were found [21].
Nine cases of encephalitis/meningitis and presumed
association with COVID-19 were reported in eight
publications. Amongst these was a case of encephalitis
in a patient with negative SARS-CoV-2 testing on
both nasopharyngeal swab and CSF (normal cell
count) in whom MRI was not performed [22].
Another patient with presumed encephalitis had nor-
mal cell count and negative SARS-CoV-2 PCR in
CSF and MRI was not performed [23]. A similar con-
stellation was reported for another case [24]. There is
one patient with a diagnosis of COVID-19-related
encephalitis for whom data could only be retrieved
from the hospital report [25]. In that case, the neuro-
logical symptoms included seizures and hiccups and
SARS-CoV-2 PCR in CSF was positive. For the case
of acute necrotizing encephalitis, a SARS-CoV-2 PCR
was not performed in CSF [26]. A pathogenesis trig-
gered by a COVID-19-related cytokine storm was sub-
sequently assumed. A positive SARS-CoV-2 PCR in
CSF was present in a patient with right temporal lobe
encephalitis and ventriculitis [27]. Two patients were
classified as having meningoencephalitis in association
with COVID-19 [28]. Both had encephalitic symp-
toms, including non-convulsive status epilepticus and
mental changes, with normal MRI and negative
SARS-CoV-2 PCR in CSF. A case of meningoen-
cephalitis was described where the patient had menin-
gism, headache, fever and seizures and was PCR
negative for SARS-CoV-2 in CSF [29].
There were five further case reports, which were
related to various aspects. There was one patient in
whom the authors assumed myelitis as the final diagno-
sis [30]. In detail, the patient had a myelopathic syn-
drome 7 days after the onset of respiratory symptoms
but was not evaluated with MRI or lumbar puncture.
There was a case of presumed acute disseminated
encephalomyelitis with only minimal contrast enhance-
ment on brain MRI [31]. CSF examination was normal
(cell count, protein, glucose) and SARS-CoV-2 PCR
was only performed for nasopharyngeal swab, which
was positive. Furthermore, there was a patient with
pre-existing epilepsy related to Herpes simplex virus
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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encephalitis who presented with non-convulsive status
epilepticus in the context of COVID-19 infection [32].
The authors discussed fever as the cause of lowering of
the threshold for seizures in a brain with structural
damage. The case of intracerebral hemorrhage that
occurred 3 days after fever and respiratory symptoms
did not have obvious coagulation disturbances [33].
Vascular imaging and CSF diagnostic were not per-
formed. A patient with headache, altered mental status,
fever and cough was classified as acute encephalopathy
[34]. Electroencephalography ruled out status epilepti-
cus, CSF showed normal results and SARS-CoV-2
PCR in CSF was not performed.
Overall, there were two patients positive for SARS-
CoV-2 PCR in CSF among the four examined
patients [25,27].
Discussion
Our systematic search yielded only a limited number
of studies and a significant reporting bias. This does
not enable an in-depth characterization of neuroinfec-
tious diseases associated with COVID-19. Indeed, the
quality, design and sample size of the available studies
prevent us from drawing conclusions on possible
direct neuroinvasive disease caused by SARS-CoV-2.
The available literature does, however, provide evi-
dence for unspecific symptoms commonly seen in viral
infections, including smell and taste disturbances and
the chance of immune-mediated peripheral nerve
involvement. Our analysis also suggests that there is
an overdiagnosis of neurological disorders due to the
inappropriate use of case definitions and restricted
exclusion of potential mimics.
Nervous system involvement has been reported dur-
ing previous coronavirus epidemics. Interestingly, the
analysis of the SARS-CoV-1 and Middle East Respira-
tory Syndrome epidemics identified only a few anecdo-
tal case reports and could not provide comprehensive
insights into the clinical and radiological picture of
neurological disease [1]. Moreover, there are pre-clini-
cal studies reporting the neuroinvasive potential of
coronaviruses and their immunogenicity [3]. The cases
of GBS that we identified in our analysis are more con-
sistent with a parainfectious disorder, i.e. a syndrome
occurring during or soon after the viral syndrome,
rather than a post-infectious syndrome. The limited lit-
erature for the COVID-19 outbreak could be seen in
the restricted documentation due to the restriction on
resources posed by the medical challenges. Indeed, it is
conceivable that most emphasis was placed on the
management of severe respiratory symptoms and
restricted intensive care unit capacity. It is obvious that
neurologists are required for the care of patients with
COVID-19 [35,36]. Their active involvement is not
only mandatory for the work-up of presumed infec-
tious and immune-mediated conditions but also for
patients with reduced consciousness and nervous sys-
tem complications of cardiac, pulmonary and coagula-
tion disturbances related to SARS-CoV-2 [36].
Moreover, hypoxic brain injury may be the reason for
clinical deterioration in a subgroup of patients. The
potential association of SARS-CoV-2 with cerebrovas-
cular diseases needs to be assessed in more detail;
prospective trials with systematic use of ancillary inves-
tigations to confirm direct and indirect mechanisms of
action are mandatory in order to gain further insights.
From a neuroinfectious viewpoint, the major limitation
of the available reports was that precise case definitions
were not used, CSF testing was performed in only a
subgroup of patients and exclusion of other potential
diagnoses was reported only on occasion. There were
just two cases with positive SARS-CoV-2 PCR in CSF
among 27 patients with potential neurological symp-
toms and proven COVID-19. However, to date, noth-
ing is known about the sensitivity of this detection
method for the examination of CSF. Indeed, CSF
examination for tick-borne encephalitis virus with
PCR is not standard due to the low sensitivity of the
method and probably also the transient presence of the
virus in CSF. The best diagnostic approach to diagnose
CNS infection with SARS-CoV-2 or parainfectious
immune reaction associated with SARS-CoV-2 remains
to be elucidated. Until now, no reports about intrathe-
cal SARS-CoV-2-specific IgG synthesis in these cases is
available but this could be key for diagnosis. In addi-
tion, a better understanding of the reported non-speci-
fic symptoms including olfactory and gustatory
disturbances, impaired consciousness and encephalopa-
thy is needed. The systemic inflammatory response is a
relevant feature of severe COVID-19 and could explain
some of these scenarios.
The current analysis tells us that we do need more
careful clinical, diagnostic and epidemiological studies
to define the manifestations and burden of neurological
disease caused by SARS-CoV-2. In this regard, we see a
clear need for the use of precise case definitions and
focused diagnostic work-up to distinguish non-specific
complications of severe disease and focused reporting
of neurological involvement in association with SARS-
CoV-2 infection. Moreover, appropriate investigations
are required to rule out other established causes of
brain infections and parainfectious disease before
attributing a condition to SARS-CoV-2. It also needs
to kept in mind that SARS-CoV-2 causes a large num-
ber of asymptomatic or mildly symptomatic infections.
A coincidental infection may exacerbate a so-far
asymptomatic or known neurological disease of other
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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causes. Here, we provide guidance for assembling key
clinical and paraclinical data that are required to estab-
lish insights into the true spectrum of direct and indirect
effects of SARS-CoV-2 infection on the nervous system
(Table 2).
1) The timing and results from nasopharyngeal swab
PCR need to be reported. Most important is the
relation to the development of respiratory and
neurological signs/symptoms. As soon as antibody
testing becomes more widely available, this will
also apply to this method. Both IgM and IgG
need to be reported. For all detection methods,
the testing kit and ideally the exact values need to
be mentioned.
2) Potential differentials need to be ruled out. Fre-
quent mimics in a report from Spain of patients
evaluated for SARS-CoV-2 infection included
hypercapnia, renal or liver failure and side-effects
of drug therapy [37]. Comorbidities are frequent
in certain patients and risk factors for neurologi-
cal complications need to be identified.
3) If neuroinvasion or immune-mediated disease of
the nervous system is suspected, it is mandatory
to perform PCR testing for SARS-CoV-2 in CSF
and anti-SARS-CoV-2 IgM/IgG testing in serum
and CSF to check for intrathecal humoral
immune reaction. It will be of major importance
to determine whether PCR in CSF specimen is
sensitive enough and to define the time window of
potential SARS-CoV-2 detection in relation to
respiratory and neurological symptoms.
The list of differential diagnoses for meningitis,
encephalitis and myelitis is extensive [38,39]. A guide is
given in Table 2. We recently summarized potential
Table 2 Recommendations for reporting of clinical features, ancillary examination in patients with severe acute respiratory syndrome coron-
avirus-2 (SARS-CoV-2) infection and nervous system involvement




Focal neurological signs Findings of neurological examination
CNS Acute/subacute, standardized definition of encephalopathy and encephalitis [16]
PNS Neurological examination, laboratory results with full myopathy panel and nerve
conduction studies/electromyography
Seizures Report semiology and seizure type according to ILAE guidelines [28]; EEG findings
according to standardized reporting
Neuroimaging Head CT Report abnormal findings, brain edema, focal contrast enhancement, vascular status
Brain MRI Abnormal findings, focal parenchymal, leptomeningeal contrast enhancement or
vasculitic changes
Spine MRI Abnormal findings, contrast-enhancement (including cranial nerves or peripheral
nerve roots in cases of suspected acute neuropathy), myelopathy/atrophy
SARS-CoV-2 viral
RNA testing
Nasopharyngeal swab Results; if multiple test performed, report time point of positive results
Immunoassay Antibodies assay (IgM/IgG titers)
CSF Results PCR (qualitative and quantitative, if available) and IgM/IgG antibodies in
CSF and serum (intrathecal SARS-CoV-2-specific antibody production)
CSF analysis Routine analysis Opening pressure, erythrocyte and leukocyte count with differential, glucose,
proteins, oligoclonal bands and IgG index
Differential for neuroinfections
and autoimmune conditions
Gram stain, bacterial culture, PCR testing for and common neurotropic viruses
(HSV, VZV, enterovirus), cryptococcal antigen testing, venereal diseases testing (if
suspected); further testing for the following infectious agents according to medical
history, immune status, age and travel history: CMV, Toxoplasma gondii,
Mycobacterium tuberculosis, Treponema pallidum, Borrelia species, opportunistic
fungal infections, tick-borne encephalitis virus, Toscana virus and West Nile virus
Laboratory serum
testing
Routine studies Cell blood count and leukocyte differentials, D-dimer, electroytes, LDH, C-reactive
protein, kidney and liver function
Infectious and autoimmune
disease






Specific drug type, dosage, route of administration
Outcome Short (7 days) and long-term outcome (3–6 months)
CMV, cytomegalovirus; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computerized tomography; EEG, electroencephalography;
HIV, human immunodeficiency virus; HSV, Herpes simplex virus; Ig, immunoglobulin; ILAE, International League Against Epilepsy; LDH,
lactate dehydrogenase; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; PNS, peripheral nervous system; RNA, ribonucleic
acid; VZV, Varicella-zoster virus.
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indications for CSF examination [1]. Briefly, a permis-
sive strategy for CSF testing should be exerted as fol-
lows.
• On suspicion of encephalitis.
• New focal neurological deficit of no plausible differ-
ential etiology or no better explanation.
• Delirious condition of no plausible differential etiol-
ogy or no better explanation.
• Acute cerebrovascular disorders.
• Convulsive or non-convulsive seizures of no plausi-
ble differential etiology or no better explanation.
• Patients in the intensive care unit with disorders of
consciousness of no plausible differential etiology or
no better explanation.
The distinction of encephalopathy and encephalitis
needs to be performed according to standard criteria
[40]. Brain MRI is critical and contrast-enhanced
sequences are mandatory [41]. Coagulation disorders
are relatively frequently encountered among patients
with COVID-19 and need to be considered in the
work-up of cerebrovascular disorders [42,43]. In cases
of peripheral nervous system involvement, nerve con-
duction studies and electromyographic findings need
to be reported and antibodies specific for immune-
mediated conditions are obligatory to evaluate for
differentials of critical illness neuropathy, acute non-
inflammatory neuropathies and myopathy [44].
4) Reporting of timing and type of treatment. There
is currently no study evidence for the efficacy of a
specific treatment for SARS-CoV-2 [45]. Guideli-
nes for the management of respiratory symptoms
and systemic complications are outlined elsewhere,
may be regionally distinct and are likely to be
updated on a regular basis. With regard to neu-
roinfectious manifestations, one should adhere to
guidance on the management of viral meningitis
and encephalomyelitis [46]. The management of
immune-mediated conditions including GBS and
Miller-Fisher syndrome should follow standard
guidelines, with intravenous Ig or plasma exchange
as first-line options [44]. Coagulation disorders and
other systemic complications of SARS-CoV-2 are
likely to be of relevance for neurological care and
complications. Although an increased risk of sei-
zures has not been reported so far, the potential
interaction of antiepileptics and antiviral/antimi-
crobial therapy needs to be kept in mind.
5) We need information on critical care illness, prog-
nostic factors and outcome.
6) The neuropathological evaluation of patients who
died from SARS-CoV-2 infection and had neuro-
logical symptoms or atypical clinical courses
could provide invaluable insights.
Conclusion
Appropriate data collection, use of precise case defini-
tions and concerted action for larger clinical studies are
required to establish a better understanding of neuroin-
vasive and immune-mediated conditions in the context
of SARS-CoV-2 infection. This is not only critical for
improved diagnosis and management but also for the
development of specific therapies in clinical treatment
trials. We therefore propose a reassessment of the avail-
able literature on neurological complications in 3–
6 months on the basis of a follow-up analysis. It would
be interesting to evaluate whether a change in the qual-
ity of the reports took place in the meantime.
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